Picture of LakeShore Biopharma Co logo

LSB LakeShore Biopharma Co Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-37.06%
3m-9.06%
6m-7.21%
1yr-69%
Volume Change (%)
10d/3m-67.07%
Price vs... (%)
52w High-62.38%
50d MA-27.95%
200d MA-9.16%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-32.15%
Return on Equity-61.69%
Operating Margin-54.35%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of LakeShore Biopharma Co EPS forecast chart

Profile Summary

LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.

Directors

    Last Annual
    March 31st, 2023
    Last Interim
    September 30th, 2023
    Incorporated
    November 28th, 2020
    Public Since
    July 30th, 2021
    No. of Employees
    773
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    188,327,959
    Blurred out image of a map
    Address
    BEIJING, 102629
    Web
    https://www.ysbiopharm.com/
    Phone
    +86 1089202086
    Auditors
    Wei, Wei & Co., LLP

    LSB Share Price Performance

    Upcoming Events for LSB

    Similar to LSB

    Picture of 60 Degrees Pharmaceuticals logo

    60 Degrees Pharmaceuticals

    us flag iconNASDAQ Capital Market

    Picture of Aadi Bioscience logo

    Aadi Bioscience

    us flag iconNASDAQ Capital Market

    Picture of Acasti Pharma logo

    Acasti Pharma

    us flag iconNASDAQ Capital Market

    Picture of Agriforce Growing Systems logo

    Agriforce Growing Systems

    us flag iconNASDAQ Capital Market

    Picture of Aptorum logo

    Aptorum

    us flag iconNASDAQ Capital Market

    FAQ